Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Hope for Chagas Disease Treatment

01.04.2005


Chagas disease, which is transmitted to humans by a blood-sucking insect known as an Assassin bug, is the most devastating parasitic infection in Central and South America and Mexico. The protozoan parasite that causes the disease, Trypanosoma cruzi, infects 16 to 18 million people, causing severe chronic illness and tens of thousands of deaths per year.



Until now, there has been no effective treatment for the long-term, chronic form of Chagas disease, which kills up to one-third of those infected, usually by heart failure. However, two Howard Hughes Medical Institute (HHMI) international research scholars have now found that in mice, a compound called TAK-187 is significantly more effective than the current standard of care - the drug benznidazole - in preventing T. cruzi-induced cardiac damage. Julio Urbina from the Venezuelan Institute for Scientific Research, Miguel Angel Basombrio from the National University of Salta, and colleagues report their findings in an early online publication of the April issue of the journal Antimicrobial Agents and Chemotherapy.

“Only one percent of the new drugs introduced to the market in the last 25 years were developed to treat tropical diseases, despite the enormous unmet need for such compounds.”
Julio Urbina



Benznidazole, a drug used to treat acute, recent Chagas infections, often has toxic side effects and does not work once the disease has entered its chronic phase. As an alternative, Urbina, Basombrio, and colleagues tested TAK-187, a compound that prevents T.cruzi from producing a member of the steroid family called ergosterol, which is essential to the parasite’s life cycle. The compound is currently in development as a systemic antifungal agent, but the results of the current study suggest that drugs of this type, which inhibit ergosterol synthesis, could be a “superior alternative to currently available therapy in the management of chronic Chagas disease,” Urbina and Basombrio write in their report.

The scientists infected a group of mice with T.cruzi, then treated those mice with either TAK-187, benznidazole, or nothing at all. While both drugs eliminated T.cruzi from the blood of infected animals, the researchers found that TAK-187 was more effective at preventing cardiac and skeletal inflammation and tissue damage, with no toxic side effects. Cardiac and skeletal damage occur in chronic Chagas infection, causing crippling and death.

Importantly, TAK-187 was effective at a dose that was both 10 times lower and administered less frequently than that of benznidazole. The researchers think this may be because the new compound is eliminated more slowly than benznidazole from the treated animals and is also more resistant to metabolism by the mammalian host.

The latest study confirms results published in 2003 by Urbina and colleagues in the International Journal of Antimicrobial Agents, when they found TAK-187 effective against drug-resistant strains of T.cruzi.

“These results, together with the previous publication, are very promising,” said Roberto Docampo, a professor at the Center for Tropical and Emerging Global Diseases at University of Georgia. “The results strongly support the view that a more efficient treatment for Chagas disease could be available.” But Louis Kirchhoff, a professor at University of Iowa, questions whether the drug is effective enough. “TAK-187 suppresses T-cruzi,” he said. “What we are looking for is a compound that wipes out the parasite.”

Urbina and colleagues now plan clinical trials to determine the safety and efficacy of TAK-187 in patients with Chagas disease. “We must now examine the safety and effectiveness of therapeutic doses of this drug and determine the optimal administration schedule, the treatment duration, and its possible combination with other drugs,” said Basombrio, who started studying the disease 28 years ago because it is so prevalent in his homeland of Argentina.

Takeda Chemical Company, the largest pharmaceutical manufacturer in Japan, has patented TAK-187 as a systemic antifungal agent. “The clinical development of this compound as an anti-T-cruzi agent in humans will depend on legal and economic agreements with Takeda, which are being sought through the World Health Organization,” said Urbina.

The Venezuelan started doing basic research on Chagas disease 25 years ago, concerned by the neglect of this tropical disease by the pharmaceutical industry and most academic research centers in Latin America and throughout the world. “Only one percent of the new drugs introduced to the market in the last 25 years were developed to treat tropical diseases, despite the enormous unmet need for such compounds,” he said. “Only 10 percent of current global health research is directed to address the medical needs of 90 percent of the human population.”

Jennifer Donovan | EurekAlert!
Further information:
http://www.hhmi.org

More articles from Health and Medicine:

nachricht Usher syndrome: Gene therapy restores hearing and balance
25.09.2017 | Institut Pasteur

nachricht MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer
25.09.2017 | Case Western Reserve University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: LaserTAB: More efficient and precise contacts thanks to human-robot collaboration

At the productronica trade fair in Munich this November, the Fraunhofer Institute for Laser Technology ILT will be presenting Laser-Based Tape-Automated Bonding, LaserTAB for short. The experts from Aachen will be demonstrating how new battery cells and power electronics can be micro-welded more efficiently and precisely than ever before thanks to new optics and robot support.

Fraunhofer ILT from Aachen relies on a clever combination of robotics and a laser scanner with new optics as well as process monitoring, which it has developed...

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Fraunhofer ISE Pushes World Record for Multicrystalline Silicon Solar Cells to 22.3 Percent

25.09.2017 | Power and Electrical Engineering

Usher syndrome: Gene therapy restores hearing and balance

25.09.2017 | Health and Medicine

An international team of physicists a coherent amplification effect in laser excited dielectrics

25.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>